NovoCure (NVCR) closed at $16.27 on Aug 4, 2026, up 6.2% on the day. The stock is down 6.1% over the past month, down 3.9% over three months, up 25.8% year to date and up 43.7% over the past year. It trades 24.2% below its 52-week high of $21.45 and 65.7% above its 52-week low of $9.82. The close sits below its 50-day moving average ($16.45) and above its 200-day moving average ($13.81).
NVCR is scheduled to report earnings on Oct 26, 2026.
NVCR options were pricing 68% at-the-money implied volatility on Oct 12, 2026, an IV rank of 21 over the past year.
NovoCure is scheduled to report on Oct 26, 2026.
Yes — the Aug 4, 2026 close of $16.27 is 17.8% above the 200-day average of $13.81.
NVCR closed 24.2% below its 52-week high of $21.45.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
